Lupin took a hit worth Rs 1,464.35 crore on US-based Gavis, which it acquired in 2015 for $880 million (Rs 5,610 crore then).

"For Lupin, migrating the portfolio from a regular oral solids to specialties would take time."

The company had reported Rs 707 crore profit for the year-ago quarter.

The business fell 13.2% to Rs 1,900.7 crore from a year earlier and contributed 46% of sales.

Gavis Pharma LLC is now exploring options to exit its listed Indian arm. Wintac Ltd was not part of the 2015 deal struck between Lupin & Ga...

Last week Dr. Reddy's acquired a portfolio of eight complex generics in the US from Teva in a deal worth $350 million.

Drug major Lupin has launched a generic insomnia drug, Zolpidem Sublingual tablets, in the US market with 180-days of marketing exclusivity.

The acquisition enhances the company's scale in the US generic market and also broadens its pipeline in dermatology and controlled substanc...

The acquisition creates the fifth largest portfolio of abbreviated new drug application (ANDA) filings with the USFDA, addressing a USD 63....

Mumbaibased pharma company Lupin has posted better-than-expected numbers after reporting dismal figures for four successive quarters.

Cipla on Friday fulfilled a longstanding desire to expand its beachhead in the US by buying Hetero Pharma’s US business for about $550 mill...

With no new blockbuster drugs going off patent in the near term, generic pharma companies have to explore new areas of growth like specialt...

The deal, which is cash-free and debt-free, widens the company's pipeline in dermatology and controlled substance products, Lupin said.

Shares of pharmaceuticals major Lupin plunged about 6% in intraday on Thursday as the company disappointed with its Q1 results.

Bill & Melinda Gates Foundation has funded two entities that have played a key role in the immunization programme and are both under fire f...

The project used vaccines that are licensed in India and that have been administered safely around the world tens of millions of times, pre...

The proposals of Agilent Technologies, Christine ComarmondMargotin, HLG Enterprises, Gstaad Hotels and three others have been rejected.